直接凝血酶抑制剂及其临床应用  

The Direct Thrombin Inhibitors and Their Clinical Application

作　　者：关键[1] 王国干[1] 朱俊[1] 

机构地区：[1]中国医学科学院中国协和医科大学阜外心血管病医院心内科急症抢救中心

出　　处：《首都医科大学学报》2007年第4期462-466,共5页Journal of Capital Medical University

摘　　要：直接凝血酶抑制剂是新兴的抗凝剂,它能抑制凝血酶,也可抑制凝血酶介导的因子Ⅴ、Ⅷ、■,纤维蛋白原及血小板的活性。它不仅有抗凝血功能,还具有抑制血小板聚集以及抗炎等作用。直接凝血酶抑制剂在临床上常用于急性冠状动脉综合征、经皮冠状动脉介入术、心房颤动、静脉血栓栓塞、肝素诱导的血小板减少、缺血性脑血管病和周围动脉闭塞性疾病等的预防和治疗。本文从直接凝血酶抑制剂的生物活性、临床应用及安全性等几个方面进行概述。Direct thrombin inhibitors are newly emerging decoagulant.They inhibit thrombin,and also inhibits factor Ⅴ,Ⅷ,■ and fibrinogen.All of which are mediated by thrombin.Direct thrombin inhibitors not only have anticoagulant function,but also have anti-platelet aggregation function.So,they have a good perspective in treatment of some diseases related to thrombus formation.In the treatment and prevention of some diseases such as acute coronary syndromes,atrial fibrillation,venous thromboembolism,heparin induced thrombocytopenia, ischemic cerebrovascular diseases,peripheral arterial occlusion,as well as during percutaneous coronary intervention,the direct thrombin inhibitor plays a role.This paper reviews the role of direct thrombin inhibitors in different aspects such as biologic activity,and safety and their clinical applications.

关 键 词：直接凝血酶抑制剂 生物学活性 安全性 临床应用 

分 类 号：R973+.2[医药卫生—药品]